Scarica l'app Stockscreener
1.06
2.75%
-0.03
Dopo l'orario di chiusura:
1.09
0.03
+2.83%
Precedente Chiudi:
$1.09
Aprire:
$1.06
Volume 24 ore:
22,536
Relative Volume:
0.41
Capitalizzazione di mercato:
$35.87M
Reddito:
-
Utile/perdita netta:
$-13.27M
Rapporto P/E:
-6.4634
EPS:
-0.164
Flusso di cassa netto:
$-7.70M
1 W Prestazione:
+0.00%
1M Prestazione:
-0.93%
6M Prestazione:
-14.52%
1 anno Prestazione:
-39.08%
Intervallo 1D:
$1.04
$1.09
Intervallo di 1 settimana:
$1.02
$1.13
Portata 52W:
$0.8075
$1.96
Okyo Pharma Limited Stock (OKYO) Company Profile
Nome
Okyo Pharma Limited
Settore
Industria
Telefono
-
Indirizzo
-
Confronta OKYO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.06 | 35.87M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Okyo Pharma Limited Borsa (OKYO) Ultime notizie
OKYO Pharma : Results of AGM 2024 - Marketscreener.com
Contrasting Genocea Biosciences (NASDAQ:GNCA) and OKYO Pharma (NASDAQ:OKYO) - Defense World
Critical Comparison: OKYO Pharma (NASDAQ:OKYO) versus enGene (NASDAQ:ENGN) - Defense World
OKYO Pharma (NASDAQ:OKYO) Trading Down 1% – What’s Next? - Defense World
OKYO Pharma to join BTIG Ophthalmology Day By Investing.com - Investing.com Canada
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference - GlobeNewswire
OKYO Pharma to join BTIG Ophthalmology Day - Investing.com
OKYO Pharma to Highlight Innovations at BTIG Conference - TipRanks
OKYO Pharma CEO to present at BTIG Ophthalmology Day - Proactive Investors USA
OKYO Pharma to Present at BTIG Ophthalmology Day, Showcases Neuropathic Pain Treatment | OKYO Stock News - StockTitan
Notice of AGM: December 2024 - Marketscreener.com
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
OKYO Pharma (LON:OKYO) Trading Down 24.3% – Here’s What Happened - Defense World
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference - Proactive Investors USA
OKYO Pharma Advances in Ocular Treatment Trials - TipRanks
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference - The Manila Times
OKYO Pharma Limited to Present at International Tear Film & Ocular Surface Society Conference - Marketscreener.com
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialICYMI - Proactive Investors Australia
OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain - Proactive Investors Australia
H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares - Investing.com India
OKYO Pharma doses first subject in OK-101 Phase II trial for NCP - Clinical Trials Arena
H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares By Investing.com - Investing.com South Africa
Wainwright sustains Buy rating on OKYO Pharma shares on clinical trial progress - Investing.com
OKYO Pharma launches Phase 2 trial for NCP treatment - Investing.com India
OKYO Pharma commences Phase 2 trial for ocular pain treatment By Investing.com - Investing.com Australia
OKYO Pharma launches Phase 2 trial for NCP treatment By Investing.com - Investing.com Australia
OKYO Pharma shares surge on Phase 2 neuropathic corneal pain trial update - Proactive financial news
OKYO Pharma commences Phase 2 trial for ocular pain treatment - Investing.com India
OKYO Pharma Begins Key Trial for Eye Pain Therapy - TipRanks
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire Inc.
Q2 Earnings Estimate for OKYO Pharma Issued By HC Wainwright - Defense World
H.C. Wainwright maintains Buy rating on OKYO Pharma shares By Investing.com - Investing.com UK
OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug - Yahoo Finance
OKYO Pharma begins phase 2 trial for NCP treatment - Investing.com
OKYO Pharma begins phase 2 trial for NCP treatment By Investing.com - Investing.com UK
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment - Proactive Investors USA
OKYO begins patient enrollment for Phase 2 NCP trial By Investing.com - Investing.com Australia
OKYO begins patient enrollment for Phase 2 NCP trial - Investing.com
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma (NASDAQ:OKYO) Shares Up 3% – What’s Next? - Defense World
Neuropathic Ocular Pain Market Overview: Size, Growth - openPR
Oklo Inc. (OKLO) is looking forward to a strong quarter - SETE News
Understanding OKLO’s book value per share for better investment insights - US Post News
XTX Topco Ltd Purchases 5,759 Shares of OneMain Holdings, Inc. (NYSE:OMF) - Defense World
Multibagger Stock under Rs 20: After stock split, Ok Play allots equities upon warrants conversion - ET Now
Okyo Pharma Limited Azioni (OKYO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):